428,099 Shares in BioLife Solutions, Inc. (NASDAQ:BLFS) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. purchased a new position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 428,099 shares of the medical equipment provider's stock, valued at approximately $11,113,000. Point72 Asset Management L.P. owned about 0.92% of BioLife Solutions as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in BLFS. D.A. Davidson & CO. grew its position in BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after purchasing an additional 519 shares in the last quarter. 1620 Investment Advisors Inc. grew its position in BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares in the last quarter. Smartleaf Asset Management LLC grew its position in BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after purchasing an additional 950 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions during the 4th quarter worth approximately $26,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in BioLife Solutions by 5.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,508 shares of the medical equipment provider's stock worth $532,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a research report on Tuesday, May 13th. Wall Street Zen cut shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.17.

Insider Activity

In related news, CMO Todd Berard sold 1,577 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now directly owns 104,961 shares in the company, valued at approximately $2,624,025. This represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sarah Aebersold sold 5,771 shares of the company's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $130,770.86. Following the completion of the sale, the insider now owns 80,094 shares of the company's stock, valued at $1,814,930.04. This represents a 6.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,696 shares of company stock worth $1,665,094 in the last ninety days. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Stock Down 1.4%

Shares of BioLife Solutions stock traded down $0.32 on Friday, hitting $21.78. 284,704 shares of the company traded hands, compared to its average volume of 385,921. The company has a 50-day moving average price of $23.20 and a 200 day moving average price of $25.20. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55. The company has a market cap of $1.03 billion, a PE ratio of -20.55 and a beta of 2.01.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. Sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.